Genetic Technologies has launched geneType, a test designed to assess the risk of developing breast and ovarian cancer in women aged 30 and above. The product was launched at the Know Your Risk event on May 22, 2024.

The test assesses cancer risk due to hereditary factors, including common gene mutations and sporadic disease. The test provides a comprehensive risk profile for developing breast or ovarian cancer, and the new addition of the germline component expands the company’s platform to screen all women at risk, whether due to gene mutations or sporadic conditions.

Genetic Technologies is a molecular diagnostics company based in Australia. It specializes in predictive genetic testing and risk assessment tools. The company operates in the market through its brands AffinityDNA, EasyDNA, and GeneType. Its key product is the GeneType Multi Test, which is a combination of geneType tests for breast, colorectal, ovarian, and prostate cancer, as well as coronary artery disease and type 2 diabetes.